Abstract: Objective To investigate the effects of different doses of recombinant human interferon α2b (rhIFNα2b) on serum silent information regulator 1 (SIRT1) levels in children with capillary bronchitis.Methods Totally 102 children with bronchiolitis admitted to our hospital from April 2021 to April 2022 were randomly divided into a control group and an observation group,with 51 cases in each group.Both groups received routine basic treatment;additionally,the control group received nebulized inhalation of rhIFN α2b injection at 100 000 IU/(kg·dose),while the observation group received nebulized inhalation of rhIFN α2b injection at 200 000 IU/(kg·dose),both being treated for 5 days.Compare the differences in clinical symptom scores,disappearance time of symptoms and signs,lung function indicators,blood gas indicators,SIRT1 and cellular immune indicators between the two groups before and 5 days after treatment,and evaluate the safety of treatment.Results After 5 days of treatment,the clinical symptom scores of cough,wheezing,wheezing rale,and triple concave syndrome in the observation group were lower than those in the control group (P<0.05).The disappearance time of various clinical indicators and hospitalization time in the observation group were shorter than those in the control group(P<0.05).After 5 days of treatment,PTEF,VT,TPTEF/TE,SaO2,PaO2,and SIRT1 in the observation group were higher than those in the control group,and their Rrs,PaCO2,EOC,and ECP were lower than those in the control group(P<0.05).Conclusion The rhIFNα2b is effective and safe in the treatment of pediatric capillary bronchitis,and compared with 100 000 IU/(kg·dose),200 000 IU/(kg·dose) is more effective in relieving clinical symptoms and signs,improving lung function and blood gas,regulating body immunity and SIRT1 levels.

Key words:

Capillary bronchitis, Recombinant human interferon α2b, Serum silencing information regulator 1, Nebulised inhalation, Prognosis